Synthetic lethality is a key therapeutic strategy extensively examined in breast cancer [1], [2], and it is among the top five cancers studied in clinical trials for this approach [3]. Furthermore, research into DNA damage response pathways [4], [5] and specific molecular targets like PI3K inhibition [6] highlights the functional relationship between synthetic lethality and breast cancer treatment.